Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How real is the thrombotic risk with the rebalancing agents used to treat hemophilia?

Journal of thrombosis and haemostasis : JTH·2026
Same author

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria.

Allergy·2026
Same author

Early Detection of Lower Adherence to Long-Term e-Diary Recording: A Checkpoint to Target Early Educational Intervention in Seasonal Allergic Rhinitis?

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

Consensus on diagnosis and management of hereditary angioedema in Greece.

European annals of allergy and clinical immunology·2025
Same author

Pathological Characterisation of Posterior Cortical Atrophy in Comparison With Amnestic Alzheimer's Disease.

Neuropathology and applied neurobiology·2025
Same author

Drivers' overall comfort experiences of reclined positions in a passenger car with an automated driving function.

Applied ergonomics·2025

Related Experiment Video

Updated: Jul 4, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Thrombin generation testing in routine clinical practice: are we there yet?

J J van Veen1, A Gatt, M Makris

  • 1Leicester Haemophilia Comprehensive Care Centre & Haemostasis and Thrombosis Unit, Leicester, UK. joost.vanveen@ukgateway.net

British Journal of Haematology
|June 20, 2008
PubMed
Summary

Thrombin generation assays show promise for personalized medicine in bleeding and clotting disorders. However, standardization is needed for reliable clinical use and to link thrombin potential to patient outcomes.

More Related Videos

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Related Experiment Videos

Last Updated: Jul 4, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Area of Science:

  • Hematology
  • Biochemistry
  • Clinical Diagnostics

Background:

  • Thrombin is a key enzyme in blood coagulation.
  • Thrombin generation potential may better reflect bleeding or clotting tendencies than traditional tests.
  • Advances in measurement techniques have spurred interest in thrombin generation assays.

Purpose of the Study:

  • To explore the correlation between thrombin generation potential and hyper-/hypo-coagulable phenotypes.
  • To assess the utility of thrombin generation assays in managing patients with bleeding disorders, on anticoagulant therapy, or with thrombotic disorders.
  • To identify the need for assay standardization for clinical application.

Main Methods:

  • Utilized fluorogenic thrombin generation assays.
  • Examined variations in assay methodologies.
  • Considered preanalytical variables impacting assay results.

Main Results:

  • Fluorogenic assays demonstrate acceptable intra-laboratory but higher inter-laboratory variation.
  • Preanalytical variable inconsistencies hinder cross-study comparisons.
  • Individual variability in thrombin generation is significant.

Conclusions:

  • Thrombin generation assays offer potential for individualized patient treatment and risk stratification.
  • Current data from large prospective studies are insufficient to establish a definitive link between thrombin generation and clinical phenotype.
  • Further assay standardization is crucial before widespread clinical adoption and multicenter studies.